Is Aptinyx Inc. (NASDAQ:APTX) Stock a Good Buy After The Recent Fall?

With aims of developing therapeutics for neurological disorders, Aptinyx Inc. (NASDAQ: APTX) is all set for a promising future (i.e., for those who have patience). The company which is a clinical-stage biopharmaceutical company has been persistently developing transformative therapies for the treatment of nervous system disorders.

Recently, the company is focused on the NMDA receptor which enhances synaptic plasticity, the foundation of neural cell communication. Putting it into layman’s language, Aptinyx is focused on developing certain drugs which would not only treat diabetic neuropathy, and Post Traumatic Stress Disorder (PSTD) but also biggest of all dementia and Parkinson’s-related plasticity issues.

The company has FDA fast-track approval for two of its drugs – one for diabetic neuropathy and the other for PTSD. When this is combined with the company’s potential to help treat people with dementia, it becomes a great prospect for the market.

Going by the numbers, though the stock of Aptinyx has not been able to perform well in the past years but then that is largely the case for most of the small biotech companies. The stock being too small fails to involve institutional traders and the individual investors trade in an amateur manner and drop out from sheer boredom.

Despite this, the company holds a tremendous promise with its three powerful products in the clinical pipeline. The company also has an edge as two of its products have been fast-tracked by the FDA. The company is making an excellent progress and the stock of Aptinyx holds promise for non-panicky investors.